New immunotherapy combo takes on advanced liver cancer
NCT ID NCT06737913
First seen Apr 12, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study tests a new way to treat advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with a blood vessel blocker (bevacizumab) and standard chemotherapy, all given directly into the liver's main artery or through a vein. The goal is to see if this mix shrinks tumors better than current options. About 76 adults with advanced liver cancer who haven't had prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug), bevacizumab (a drug that blocks blood vessel growth), and FOLFOX chemotherapy (a combination of three chemo drugs)
What this could lead to
If this works, it could offer a new first-line treatment option for advanced liver cancer that has spread, potentially shrinking tumors and extending life.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 76 people, so results may not apply to everyone. The combination of drugs can cause serious side effects like immune reactions, bleeding, or liver damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.